Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of GLPG1690 in idiopathic pulmonary fibrosis
MOH_2019-02-24_005991Phase 3Not yet recruiting
- Sponsor
- Galapagos NV
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoint: Primary endpoint not provided. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2019-02-24_005991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-24_005991.